A Phase 3b randomized clinical trial has shown that combining ixekizumab with tirzepatide significantly improves both skin clearance and weight reduction in adults with moderate-to-severe plaque psoriasis and overweight or obesity.
Psoriasis is closely linked to obesity, with 60 to 78 percent of patients estimated to be overweight or obese. Excess weight is tied to more severe disease, poorer treatment response, and worse cardiometabolic outcomes. Until now, few trials have explored simultaneous management of these conditions.
In this multicenter, open-label study, 274 adults from 72 U.S. sites were randomized to receive either ixekizumab plus tirzepatide or ixekizumab alone, along with diet and exercise counseling. The primary endpoint at Week 36 was achieving complete skin clearance (PASI 100) and a weight reduction of at least 10 percent.
Results showed 27.1 percent of patients on the combination therapy met that goal, compared to only 5.8 percent on ixekizumab alone. Complete skin clearance alone was also higher: 40.6 percent versus 29 percent. Weight loss of 10 percent or more occurred in 69.2 percent of combination patients versus 9.1 percent on monotherapy. Nearly 80 percent of the combination group achieved PASI 75 with at least 5 percent weight loss.
Safety profiles were consistent with known effects of each drug. Gastrointestinal issues were more common in the combination group, reflecting tirzepatide's known side effects. Injection-site reactions were also reported. No new safety signals emerged.
The authors conclude that this dual therapy may be a promising strategy for difficult-to-treat psoriasis in patients with obesity, potentially improving both skin and cardiometabolic health.